A Dose of Hope: Cognition's CT1812 Proves Its Mettle in Alzheimer's Aβ Oligomer Displacement

Cognition Therapeutics Inc CGTX announces data publication from a Phase 1b SNAP trial of CT1812 to Measure Aβ Oligomer Displacement in Alzheimer's Disease in the Translational Neurodegeneration journal.

"By evaluating hourly changes in beta-amyloid (Aβ) oligomer concentrations in the cerebrospinal fluid (CSF) of individuals with mild-to-moderate Alzheimer's disease, we were able to observe the impact of CT1812 target engagement," stated Mary Hamby, VP of research.

"Data from the Phase 1b SNAP study mirror findings from our preclinical studies showing Aβ oligomer displacement from neurons in culture and into the CSF in transgenic mice," Hamby added.

Findings from the SNAP study demonstrate that a single oral dose of CT1812 rapidly displaces Aβ oligomers from synapses. 

This was shown by a marked temporal increase in CSF Aβ oligomer levels after a single dose of CT1812. 

No change was observed in Aβ oligomer levels after the placebo administration. 

In this study of three individuals with Alzheimer's disease, CT1812 was well-tolerated, and no serious adverse events were related to the study medication but instead were due to the lumbar puncture procedure for the indwelling catheter used for CSF sampling.

Price Action: CGTX shares are up 14.70% at $2.00 on the last check Thursday.